10-Q quarterly report · filed Nov 3, 2026

RxSight, Inc. (RXST) Q3 2026 10-Q Quarterly Report

Short answer

RxSight, Inc. (RXST) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M (down 19.1% year over year) with net income of −$16M.

Q3 2026 key financials · XBRL

Revenue
$25M
−19.1% YoY · −9.9% QoQ
Net income
−$16M
−65.3% YoY · −34.1% QoQ
Operating margin
-75.4%
EPS (diluted)
−$0.39
−62.5% YoY · −30.0% QoQ

Source: XBRL data from the RxSight, Inc. (RXST) Q3 2026 10-Q on SEC EDGAR. USD.

RxSight, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $24.6M, down 19.0% YoY from $30.3M, amid increased IOL competition
  • Product gross margin 73.6% vs 79.9% YoY, pressured by inventory reserves and higher-cost inventory
  • LAL sales $22.8M vs $25.7M YoY, while LDD sales fell to $3.2M from $4.1M
  • Cash, equivalents and short-term investments $254.7M; operating cash flow $24.8M vs $(14.4)M YoY
  • Near-term outlook: renewed revenue growth expected from commercial realignment, with competitive trialing and excess LDD inventory as headwinds

Risk Factors

  • New risk from June 2026 Alcon collaboration: $70M feasibility and $40M approval milestones remain optional and contingent
  • Most material update: LDD manufacturing paused in Q3 2026 after declining sales, creating inventory write-down and margin risks
  • Regulatory risk: QMSR became effective February 2026, requiring compliant manufacturing processes for continued commercialization
  • Near-term market risk: sales declined through Q3 2026, while premium LAL demand remains sensitive to patient out-of-pocket spending
  • Financial risk: $254.7M cash, equivalents and short-term investments held with one financial institution as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other RxSight, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.